Study shows Alzheimer’s drugs may boost protein, not just lower amyloid
Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, the drugs boost levels of a healthy form of amyloid beta (Aβ42) protein in the brain,
Alzheimer's Drugs May Work in Whole New Way, Study Finds
Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years. It's thought the drugs curb Alzheimer's by reducing levels of toxic amyloid protein plaques in the brain.
Study finds Alzheimer's drugs might boost healthy protein in brain
Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years. It's thought the drugs curb Alzheimer's by reducing levels of ...
Alzheimer's Decline May Be Slowed by Protein Boost
Have we been wrong about what causes Alzheimer's disease? New research suggests yes. For years, the leading theory for the cause of this neurodegeneration was the accumulation of abnormal proteins in and around our brain cells.
Boosting brain protein levels may slow decline from Alzheimer's
A study found that new monoclonal antibody drugs for Alzheimer's may slow cognitive impairment through boosting levels of a specific protein in the brain.
NBC261d
FDA approves new Alzheimer's drug to slow disease progression
The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...
Kearney Hub1d
'This is why we walk': New drug that may slow Alzheimers now offered in Kearney area
Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.
Eli Lilly to invest $1.8 billion to expand manufacturing for weight loss, diabetes and Alzheimer's drugs
Demand for Eli Lilly’s Zepbound and Mounjaro has outstripped supply over the last year, forcing the company to invest heavily ...
BioSpace6d
Late-Stage Alzheimer’s Pipeline Goes Beyond Amyloid and Tau
The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple ...
6 Incredible Reasons to Invest in Eli Lilly
Sold under the brand names Mounjaro and Zepbound, tirzepatide has been an incredible growth driver for Eli Lilly. In 2022 -- ...
Hartsville patient one of first in U.S. to get new Alzheimer’s treatment
A Hartsville hospital patient is among the first in the United States to receive a new treatment that helps slow the ...
Hope for Alzheimer's: Q&A with neurological disease expert
For Lennart Mucke, MD, founding director of the Gladstone Institute of Neurological Disease, these new drugs mark an ...
Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly
Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs ...
Citi resumes coverage of Eli Lily with a Buy rating: Should you invest?
Discover Citi's bullish outlook on Eli Lilly with a $1,060 target. Is now the time to invest? Find key insights and price ...